Long intergenic non-protein coding RNA 624 (LINC00624)

Long intergenic non-protein coding RNA 624 (LINC00624) is a long non-coding RNA gene located on chromosome 1 (1q21.1), expressed from the reverse strand. It does not encode a protein but functions as a regulatory RNA. LINC00624 has been implicated in promoting cancer progression, notably hepatocellular carcinoma and HER2+ breast cancer, by acting as a molecular decoy for transcriptional repressor complexes (HDAC6-TRIM28-ZNF354C), regulating histone deacetylase activity, and modulating transcription of oncogenic factors such as CHD1L and BCL9. In breast cancer, LINC00624 fosters immune escape and resistance to HER2-targeted therapy by stabilizing ADAR1 and suppressing interferon-driven immune responses, notably inhibiting antigen presentation and CD8+ T cell infiltration. Its overexpression is associated with poor responses to standard therapies and has potential as both a therapeutic target and a biomarker for tumor aggressiveness and therapy resistance. There are currently no approved drugs targeting LINC00624, though antisense oligonucleotide therapies are under investigation.

Other names

Long intergenic non-protein coding RNA 624LINC00624LOC100509137ENSG00000278811

Drugs (e.g., lapatinib, trastuzumab) face resistance mediated by LINC00624 overexpression, particularly through immune pathway inhibition involving type I interferon signaling and ADAR1-dependent RNA editing. Antisense oligonucleotides targeting LINC00624 could disrupt its function and restore therapeutic efficacy.